Skip to main content
Top
Published in: Clinical and Translational Oncology 12/2017

Open Access 01-12-2017 | Research Article

Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique

Authors: M. Nicoś, P. Krawczyk, K. Wojas-Krawczyk, A. Bożyk, B. Jarosz, M. Sawicki, T. Trojanowski, J. Milanowski

Published in: Clinical and Translational Oncology | Issue 12/2017

Login to get access

Abstract

Purpose

RT-PCR technique has showed a promising value as pre-screening method for detection of mRNA containing abnormal ALK sequences, but its sensitivity and specificity is still discussable. Previously, we determined the incidence of ALK rearrangement in CNS metastases of NSCLC using IHC and FISH methods.

Materials

We evaluated ALK gene rearrangement using two-step RT-PCR method with EML4-ALK Fusion Gene Detection Kit (Entrogen, USA). The studied group included 145 patients (45 females, 100 males) with CNS metastases of NSCLC and was heterogeneous in terms of histology and smoking status.

Results

21% of CNS metastases of NSCLC (30/145) showed presence of mRNA containing abnormal ALK sequences. FISH and IHC tests confirmed the presence of ALK gene rearrangement and expression of ALK abnormal protein in seven patients with positive result of RT-PCR analysis (4.8% of all patients, 20% of RT-PCR positive patients). RT-PCR method compared to FISH analysis achieved 100% of sensitivity and only 82.7% of specificity. IHC method compared to FISH method indicated 100% of sensitivity and 97.8% of specificity. In comparison to IHC, RT-PCR showed identical sensitivity with high number of false positive results.

Conclusion

Utility of RT-PCR technique in screening of ALK abnormalities and in qualification patients for molecularly targeted therapies needs further validation.
Literature
1.
go back to reference Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.CrossRefPubMedPubMedCentral Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.CrossRefPubMedPubMedCentral
2.
go back to reference Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.CrossRefPubMed Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.CrossRefPubMed
3.
go back to reference Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14:6618–24.CrossRefPubMed Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14:6618–24.CrossRefPubMed
4.
go back to reference Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723–33.CrossRefPubMed Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723–33.CrossRefPubMed
5.
go back to reference Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87:211–9.CrossRefPubMed Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87:211–9.CrossRefPubMed
6.
go back to reference Shi W, Dicker AP. CNS metastases in patients with non-small-cell lung cancer and ALK gene rearrangement. J Clin Oncol. 2016;34:107–9.CrossRefPubMed Shi W, Dicker AP. CNS metastases in patients with non-small-cell lung cancer and ALK gene rearrangement. J Clin Oncol. 2016;34:107–9.CrossRefPubMed
7.
go back to reference Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, Immunohistochemistry, and real-time quantitative RT-PCR on paraffin-embedded tissues. PLoS One. 2013;8:e64821.CrossRefPubMedPubMedCentral Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, Immunohistochemistry, and real-time quantitative RT-PCR on paraffin-embedded tissues. PLoS One. 2013;8:e64821.CrossRefPubMedPubMedCentral
8.
go back to reference Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–59.CrossRefPubMedPubMedCentral Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–59.CrossRefPubMedPubMedCentral
9.
go back to reference Tsao MS, Hirsch FR, Yatabe Y. IASLC atlas of ALK and ROS1 testing in lung cancer. IASLC 2016; Aurora. Tsao MS, Hirsch FR, Yatabe Y. IASLC atlas of ALK and ROS1 testing in lung cancer. IASLC 2016; Aurora.
10.
go back to reference Wang J, Cai Y, Dong Y, Nong J, Zhou L, et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS One. 2014;9:e101551.CrossRefPubMedPubMedCentral Wang J, Cai Y, Dong Y, Nong J, Zhou L, et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS One. 2014;9:e101551.CrossRefPubMedPubMedCentral
11.
go back to reference Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res. 2014;3:70–4.PubMedPubMedCentral Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res. 2014;3:70–4.PubMedPubMedCentral
12.
go back to reference Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated protein like 4–anaplastic lymphoma kinase fusion-positive non–small cell lung carcinoma. Arch Pathol Lab Med. 2012;136:796–803.CrossRefPubMed Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated protein like 4–anaplastic lymphoma kinase fusion-positive non–small cell lung carcinoma. Arch Pathol Lab Med. 2012;136:796–803.CrossRefPubMed
14.
go back to reference Tuononen K, Sarhadi WK, Wirtanen A, Rönty M, Salmenkiv K, et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by fish, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed Res Int. 2013. doi:10.1155/2013/757490.PubMedPubMedCentral Tuononen K, Sarhadi WK, Wirtanen A, Rönty M, Salmenkiv K, et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by fish, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed Res Int. 2013. doi:10.​1155/​2013/​757490.PubMedPubMedCentral
15.
go back to reference Nicoś M, Jarosz B, Krawczyk P, Wojas-Krawczyk K, Kucharczyk T, et al. Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer. Brain Pathol. 2016. doi:10.1111/bpa.12466.PubMed Nicoś M, Jarosz B, Krawczyk P, Wojas-Krawczyk K, Kucharczyk T, et al. Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer. Brain Pathol. 2016. doi:10.​1111/​bpa.​12466.PubMed
16.
go back to reference Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res. 2014;20:2029–34.CrossRefPubMed Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res. 2014;20:2029–34.CrossRefPubMed
18.
go back to reference Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3383–9.CrossRefPubMed Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3383–9.CrossRefPubMed
19.
go back to reference Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012;7(2):e31323.CrossRefPubMedPubMedCentral Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012;7(2):e31323.CrossRefPubMedPubMedCentral
20.
go back to reference Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13–7.CrossRefPubMed Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13–7.CrossRefPubMed
21.
go back to reference Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012;18:5682–9.CrossRefPubMed Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012;18:5682–9.CrossRefPubMed
22.
go back to reference Lantuejoul S, Rouquette I, Blons H, Le Stang N, Ilie M, et al. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J. 2015;46:207–18.CrossRefPubMed Lantuejoul S, Rouquette I, Blons H, Le Stang N, Ilie M, et al. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J. 2015;46:207–18.CrossRefPubMed
23.
go back to reference Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012;18:4682–90.CrossRefPubMed Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012;18:4682–90.CrossRefPubMed
24.
go back to reference Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, et al. RAS-MAPK dependence underlies a rational poly-therapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21:1038–47.CrossRefPubMedPubMedCentral Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, et al. RAS-MAPK dependence underlies a rational poly-therapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21:1038–47.CrossRefPubMedPubMedCentral
Metadata
Title
Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique
Authors
M. Nicoś
P. Krawczyk
K. Wojas-Krawczyk
A. Bożyk
B. Jarosz
M. Sawicki
T. Trojanowski
J. Milanowski
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1676-4

Other articles of this Issue 12/2017

Clinical and Translational Oncology 12/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine